According to a research report published this morning, J.P. Morgan has increased Covidien's COV PT from $59 to $64.
J.P. Morgan commented in the report, "We're reiterating our Overweight and Top Pick rating on Covidien this morning and raising our December 2012 price target to $64. Organic growth is accelerating (+5.8% in the March quarter) and margins are expanding (GM +110bps YTD, OM +100bps), while the broader industry continues to struggle (1Q organic revenue growth in large-cap MedTech: 3.1%). Covidien is, in short, pulling away from the pack."
Covidien closed yesterday at $54.25.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in